Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Ramantamig’s trispecific targeting of BCMA and GPRC5D may overcome antigen heterogeneity in multiple myeloma

  • By

  • Chloe O'Neill

  • Marloes E. C. Broekmans

  • Charlotte L. B. M. Korst

  • Maria Krevvata

  • Giada Dal Collo

  • Richard W. Groen

  • Bing Li

  • Serena R. Baglio

  • Ulrike Philippar

  • Kodandaram Pillarisetti

  • Sonja Zweegman

  • Deeksha Vishwamitra

  • Tuna Mutis

  • Niels W. C. J. van de Donk

  • October 7, 2026

Share

  • 1

    Ramantamig is a trispecific antibody that engages CD3 on T cells and targets BCMA and GPRC5D on multiple myeloma cells.

  • 2

    Variable BCMA and GPRC5D expression and genetic or epigenetic target inactivation can contribute to resistance to single-target bispecific antibodies.

  • 3

    The study assessed ramantamig activity against myeloma cell lines using healthy-donor T cells and against primary myeloma cells in 32 patient bone marrow samples.

  • 4

    The patient bone marrow samples contained 1% to 68% myeloma cells, with a median of 15%, and assays used autologous effector cells.

  • 5

    Ex vivo efficacy was evaluated by measuring surviving CD138-positive myeloma cells after 48 hours of exposure to ramantamig or control antibodies.

Original Source(s)

Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma

  • by Chloe O'Neill, Marloes E. C. Broekmans, Charlotte L. B. M. Korst, Maria Krevvata, Giada Dal Collo, Richard W. Groen, Bing Li, Serena R. Baglio, Ulrike Philippar, Kodandaram Pillarisetti, Sonja Zweegman, Deeksha Vishwamitra, Tuna Mutis, Niels W. C. J. van de Donk

  • October 7, 2026

Related Content

Error in Supplement 2

  • October 19, 2026

Personalized Breast Cancer Screening: Moving Beyond Age-Based Algorithms

Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.

  • by

  • October 16, 2026

  • 7 min
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy